Stocks›Healthcare›ROIV

ROIV

ROIVANT SCIENCES LTD.

NasdaqResearch view

$35.80−0.91%

Sep 25 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsLarge-capSEC EDGAR FY 2026-03-31

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 10, 2025 and Nov 12, 2024, before the open.

Last report

Aug 6, 2026+1.50%

before the open

Last 4, next close

median 8.33% either way

up 4 of 4

Every report since 2023 →

DateEventSourceNext close

Aug 27Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.GlobeNewswireGlobeNewswire+2.26%
Aug 6Earnings release, before the open · 8-KSEC EDGARSEC EDGAR ↗+1.50%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

17 big days: a close more than 4.02% from the one before, three times ROIV’s median day (1.34%). On 1 of 17, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, May 26, 2026

17Sep 8, 2026
Sep 8, 2026Nothing in our recordNo ROIV story, brief or results filing in our record that dayGroup −2.2% did not move with it
−2.2% did not move with itABBV −3.0 · JNJ −2.2 · LLY −2.2 · MRK −1.2
+18.75%
16Aug 28, 2026
Aug 28, 2026Nothing in our recordNo ROIV story, brief or results filing in our record that dayGroup −0.5% did not move with it
−0.5% did not move with itABBV −1.0 · JNJ +0.8 · MRK −0.8 · LLY −0.1
−7.64%
15Jul 30, 2026
Jul 30, 2026Nothing in our recordNo ROIV story, brief or results filing in our record that dayGroup −3.0% did not move with it
−3.0% did not move with itLLY −4.5 · JNJ −3.7 · ABBV −2.2 · MRK −0.4
+5.02%
14Jul 13, 2026
Jul 13, 2026Nothing in our recordNo ROIV story, brief or results filing in our record that dayGroup +0.1% did not move with it
+0.1% did not move with itLLY −0.6 · MRK +0.4 · JNJ +0.3 · ABBV −0.0
−4.06%
13Jun 24, 2026
Jun 24, 2026Nothing in our recordNo ROIV story, brief or results filing in our record that dayGroup +0.8% did not move with it
+0.8% did not move with itLLY +0.9 · MRK +0.8 · JNJ +0.8 · ABBV +0.1
+5.59%
12Jun 11, 2026
Jun 11, 2026Nothing in our recordNo ROIV story, brief or results filing in our record that dayGroup +0.7% did not move with it
+0.7% did not move with itLLY +2.2 · MRK +1.4 · ABBV −0.1 · JNJ −0.1
+4.65%
11May 21, 2026
May 21, 2026Before our storiesGroup +1.6% did not move with it
+1.6% did not move with itMRK +2.5 · LLY +2.2 · JNJ +1.1 · ABBV +1.0
−4.72%
10May 20, 2026
May 20, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.5% did not move with it
−0.5% did not move with itMRK −1.1 · ABBV −0.7 · JNJ −0.3 · LLY −0.3
+14.89%
9Mar 31, 2026
Mar 31, 2026Before our storiesGroup +1.9% did not move with it
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.9 · JNJ +0.8
+4.88%
8Mar 4, 2026
Mar 4, 2026Before our storiesGroup −0.0% did not move with it
−0.0% did not move with itABBV +1.0 · JNJ −0.6 · LLY −0.4 · MRK +0.4
+6.00%
7Feb 9, 2026
Feb 9, 2026Before our storiesGroup −0.9% did not move with it
−0.9% did not move with itMRK −3.5 · LLY −1.3 · JNJ −0.6 · ABBV −0.1
+7.16%
6Feb 6, 2026
Feb 6, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +1.9% did not move with it
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.8 · JNJ +0.9
+22.14%
5Jan 13, 2026
Jan 13, 2026Before our storiesGroup −0.0% did not move with it
−0.0% did not move with itJNJ +1.9 · MRK −0.8 · LLY −0.3 · ABBV +0.3
+5.78%
4Dec 16, 2025
Dec 16, 2025Before our storiesGroup −1.8% did not move with it
−1.8% did not move with itJNJ −2.3 · MRK −2.0 · ABBV −1.7 · LLY −0.7
+4.75%
3Dec 11, 2025
Dec 11, 2025Before our storiesGroup +1.5% did not move with it
+1.5% did not move with itJNJ +1.7 · LLY +1.6 · MRK +1.4 · ABBV −0.5
+5.43%
2Oct 30, 2025
Oct 30, 2025Before our storiesGroup +1.3% did not move with it
+1.3% did not move with itLLY +3.8 · ABBV +1.4 · JNJ +1.3 · MRK −0.3
+4.37%
1Oct 1, 2025
Oct 1, 2025Before our storiesGroup +6.5% moved the same way
+6.5% moved the same wayLLY +8.2 · MRK +7.4 · ABBV +5.5 · JNJ +0.3
+4.10%

A story on the same day is not a cause, and a group move is not proof either. Group: LLY, JNJ, ABBV, MRK, the largest companies in ROIV’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2026, filed

SEC EDGAR

Market cap$25.9B

Revenue$8.3M−71.60%

Net income$-299.8M

EPS, diluted$-0.54−125.00%

Operating margin-6235.7%

Return on equity-5.7%

Debt / equity0.06

All filed figures

Snapshot

SEC EDGAR · FY 2026-03-31

SectorHealthcare

Market Cap$25.9B

Enterprise Value$24.8B

Income$-299.8M

Sales$8.3M

Book/sh$7.33

Cash/sh$1.98

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio18.25

Current Ratio18.37

Debt/Eq0.06

EPS (ttm)$-0.54

EPS this Y-125.0%

EPS past 3/5Y—

Sales past 3/5Y-36.0%

EPS Y/Y TTM-125.0%

Sales Y/Y TTM-71.6%

Shs Outstand722.32M

ROA-5.3%

ROE-5.7%

ROIC-18.5%

Gross Margin—

Oper. Margin-6235.7%

Profit Margin-3629.2%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$55.3M

FY22

$31.5M

FY23

$32.7M

FY24

$29.1M

FY25

$8.3M

FY26

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	$55.3M	$31.5M	$32.7M	$29.1M	$8.3M
Gross Profit	—	—	—	—	—
Operating Income	$-1.4B	$-906.8M	$4.5B	$-1.0B	$-515.1M
Net Income	$-845.3M	$-1.0B	$4.3B	$-172.0M	$-299.8M
Diluted EPS	$-1.26	$-1.42	$5.23	$-0.24	$-0.54
Operating Cash Flow	$-677.7M	$-843.4M	$-765.3M	$-839.5M	$-750.3M
Free Cash Flow	$-695.2M	$-856.1M	$-766.6M	$-844.0M	$-758.6M

Same industry

In the screener →

LLY$1.11T JNJ$653.6B ABBV$467.1B MRK$367.1B ABT$175.3B PFE$163.4B VRTX$133.4B BMY$128.4B

Follow the news. Track the move.

ROIV story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Regulation

Aug 27

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Roivant said the FDA approved once-daily LISRAYA for adults with dermatomyositis, with the pill now available in the United States. The approval opens a commercial opportunity, but the company’s latest reported revenue was $8.3M, down 71.6% year over year, against a net margin of -3629.2%.

Since story

-4.7%

2026-08-27 → 2026-09-25

GlobeNewswire · 30d ago

View both sides →

Follow the news. Track the move.